China's Xinjiang plans to open up to more tourists
The Xinjiang Uygur autonomous region, which stretches over a vast tract of land in western China, has become a hugely popular destination among domestic tourists in recent years, receiving a record 302 million visits last year.
Now, local officials have published an action plan to further grow the region's culture and tourism sector, with a target of raising the industry's annual revenue to at least 1 trillion yuan (US$138 billion) and receiving at least 400 million visits per year by 2030, according to the document published on Sunday.
The plan will involve opening up the region to more foreign tourists, with the document including references to strengthening the development of cross-border tourism and expanding trade in cultural goods and services.
Xinjiang – which is famous in China for its stunning natural scenery and diverse mix of ethnic groups – is not currently fully open to foreign nationals.
While international visitors can generally enter the region freely, they normally need special permits to visit some tourist attractions, such as the huge Bayinbuluke grassland, according to China-based travel agencies that organise trips for foreigners.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
South China Morning Post
an hour ago
- South China Morning Post
Why some Chinese students are skipping elite universities amid job market fears
After underperforming in China's national college entrance exam in June, Lu Jie was accepted into a computer science and technology programme earlier this month at a lesser-known polytechnic university in central China's Hunan province. 'Good schools had too many applicants for this major, so I had to choose a lower-ranked one to pursue it,' Lu said. The results for the exam, better known as the gaokao , have been released over the past two weeks – marking a life-changing moment for students like Lu. Now more than ever, students are opting for majors with strong job prospects over prestigious universities. A focus on immediate employability and job security is eclipsing long-term aspirations and personal interests. Driving this trend is a growing oversupply of college graduates , intensifying competition in the job market amid a challenging economic climate. Computer science has long been a highly popular major, Lu said, but the rise of artificial intelligence (AI) – widely expected to create new job opportunities – has fuelled even greater demand over the past couple of years.
South China Morning Post
2 hours ago
- South China Morning Post
GSK signs US$12.5 billion licence deal with Hengrui as China rises in global pharmaceuticals
GlaxoSmithKline (GSK) will pay a Chinese company US$12.5 billion for exclusive global rights to develop a dozen drugs, in a landmark deal that underscores how China's research labs are snapping up market share in the global pharmaceutical and biomedical industries. Advertisement The deal would give GSK the rights to develop a drug for treating chronic obstructive pulmonary disease (COPD) called HRD-9821, as well as 11 of the preclinical programmes owned by Jiangsu Hengrui Pharmaceuticals. The global rights exclude mainland China, Taiwan, Hong Kong and Macau, according to a statement to the Hong Kong stock exchange on Monday. The deal is the latest in a string of transactions between multinational firms and Chinese drug developers, which have bolstered China's share of global licensing deal value to 28 per cent in 2024 from 1 per cent in 2019. Pfizer agreed in May to pay US$1.25 billion to Shenyang-based 3SBio for the exclusive right to develop the Chinese company's drug for treating solid tumours. China's pharmaceutical out-licensing value soared to almost US$66 billion in the first six months of 2025, more than the whole of last year, according to a July 14 report from China Post Securities. For multinational companies, the deals gave them exclusive products to expand their product portfolio and pipelines, while the Chinese developers saw them as opportunities to cash in on prior work and fund new projects. The corporate flag of GlaxoSmithKline (GSK) next to a Chinese national flag outside a GlaxoSmithKline office building in Shanghai on July 12, 2013. Photo: Reuters Hengrui, established in the Jiangsu provincial city of Lianyungang in 1997, would receive a US$500 million upfront payment and charge US$12 billion to GSK upon the achievement of development, regulatory approval and sales milestones. Advertisement 'The signing of the agreement will help expand the international market for HRS-9821 and multiple innovative medicines in various therapeutic areas, including oncology, respiratory, immunology and inflammation, providing high-quality treatment options for patients worldwide,' Hengrui said in a statement.
South China Morning Post
3 hours ago
- South China Morning Post
InvestHK at 25: powering growth for global firms in Hong Kong and beyond
When InvestHK was established in July 2000, its mission was clear: attract overseas and mainland Chinese companies to establish or expand in Hong Kong, reinforcing its position as 'Asia's world city'. Twenty-five years on, that mission remains unchanged, but the tools and the scale of support have evolved significantly. Advertisement This year, both InvestHK and Hong Kong Exchanges and Clearing (HKEX) marked their silver jubilees with notable results. In 2024, InvestHK assisted a record 539 mainland Chinese and overseas companies in setting up operations in Hong Kong. Since its establishment in 2000, 145 of InvestHK's clients have listed on HKEX. Between January 2023 and June 2025, InvestHK helped more than 1,300 companies set up or expand in Hong Kong, bringing in over HK$160 billion (US$20 billion) in foreign direct investment. These companies created more than 19,000 jobs in their first year of operation, exceeding the government's 2022 Policy Address targets ahead of schedule. Hong Kong's initial public offering (IPO) market has maintained steady momentum in 2025, with HKEX recording more than 50 listings between January and mid-July, a year-on-year increase of 30 per cent. The exchange ranked first globally in IPO fundraising during the period, with more than 200 companies actively preparing for a public offering in the second half of the year. Support from InvestHK for overseas and mainland Chinese companies and institutions includes planning, setting up and expanding their operations in Hong Kong. The agency provides strategic advice on market entry, practical guidance during the establishment and launch phases, and continued support as businesses grow and scale across international markets via Hong Kong. When an IPO is on the horizon, InvestHK offers pre-listing workshops covering disclosure, environmental, social and governance (ESG), and investor-relations requirements, enabling founders to scale up without needing to shift jurisdictions, a stability that is increasingly valued in an era of geopolitical uncertainty. Advertisement Beyond projects: building ecosystems
